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SUMMARY
Fetal globin genes are transcriptionally silenced
during embryogenesis through hemoglobin switch-
ing. Strategies to derepress fetal globin expression
in the adult could alleviate symptoms in sickle
cell disease and b-thalassemia. We identified a
zinc-finger protein, pogo transposable element
with zinc-finger domain (POGZ), expressed in
hematopoietic progenitor cells. Targeted deletion
of Pogz in adult hematopoietic cells in vivo
results in persistence of embryonic b-like globin
expression without affecting erythroid develop-
ment. POGZ binds to the Bcl11a promoter and
erythroid-specific intragenic regulatory regions.
Pogz+/! mice show elevated embryonic b-like
globin expression, suggesting that partial reduc-
tion of Pogz expression results in persistence of
embryonic b-like globin expression. Knockdown
of POGZ in primary human CD34+ progenitor cell-
derived erythroblasts reduces BCL11A expre-
ssion, a known repressor of embryonic b-like
globin expression, and increases fetal hemoglobin
expression. These findings are significant, since
new therapeutic targets and strategies are needed
to treat b-globin disorders.
INTRODUCTION
During mouse embryonic development, three distinct popula-
tions of erythroid cells are generated (Baron et al., 2013). The first
are primitive erythroid cells, which arise from the yolk sac and
mainly express embryonic b-like globins (Hbb-bh1 and Hbb-y)
and low levels of adult-type globins (Hbb-b1 and Hbb-b2)
(Kingsley et al., 2006; Palis, 2014). The second are definitive
erythroid cells from the yolk sac that seed the fetal liver (FL).
Initially, they express Hbb-bh1 and Hbb-y and then switch to
Hbb-b1 and Hbb-b2 expression (McGrath et al., 2011). The third
population is hematopoietic stem cells (HSCs) that arise from
intra-embryonic sites, including the aorta-gonad mesonephros
region, that initially seed the FL and then home to the bone
marrow and give rise to definitive erythroid cells. These erythroid
cells express the adult Hbb-b1 and Hbb-b2 globins.
Sickle cell disease (SCD) and b-thalassemia are inherited
human hemoglobin disorders, which result from globin gene
mutations and represent a significant global health issue. Natural
variations in fetal hemoglobin expression have been linked to the
severity of disease outcome, such that individuals with higher
fetal hemoglobin levels have less severe symptoms in SCD
and b-thalassemia (Sankaran et al., 2010a). Genome-wide asso-
ciation studies identified three loci associated with increased
fetal hemoglobin levels (Galarneau et al., 2010; Lettre et al.,
2008; Uda et al., 2008), including BCL11A, which was subse-
quently shown to function as a transcriptional repressor of fetal
hemoglobin (Sankaran et al., 2008). Conditional loss of Bcl11a
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in erythroid cells leads to increased embryonic b-like globin
expression without affecting normal erythroid development,
suggesting that BCL11A is a relevant therapeutic target (Xu
et al., 2011). Recent experimental evidence confirmed that loss
of Bcl11a expression in a preclinical model of SCD reversed
sickling and end organ damage (Xu et al., 2011). Embryonic
b-like globin is maintained in a repressed state by a multi-protein
co-repressor complex, including BCL11A, GATA1, SOX6, and
chromatin remodeling proteins, including Mi2b, HDAC1/2,
LSD1/CoREST, and DMMT1 (Xu et al., 2010, 2013). These and
other targets represent therapeutic opportunities to reactivate
fetal globin to treat SCD and b-thalassemia (Bauer et al., 2012;
Sankaran et al., 2008; Xu et al., 2013).
We identified a previously uncharacterized transcriptional
regulator of hematopoiesis, POGZ (KIAA0461, ZNF280E), in a
screen of a human hematopoietic progenitor cell line model
(KG1) and its more differentiated progeny (Gudmundsson
et al., 2007). POGZ is a zinc-finger containing protein, which
binds to SP1, LEDGF, and heterochromatin proteins (Bartholo-
meeusen et al., 2009; Gunther et al., 2000; Nozawa et al.,
2010), suggesting POGZ may have an important role in gene
regulation; however, its function in hematopoiesis is currently
unknown (Gudmundsson et al., 2007; Ishikawa et al., 1997; No-
mura et al., 1994; Okazaki et al., 2003). Domain structure predic-
tions by SMART analysis (Letunic et al., 2009; Schultz et al.,
1998) indicate that POGZ has at least 8 C2H2 zinc fingers, sug-
gesting it can bind DNA (Figure S1A). We show here that Pogz is
expressed in normal mouse hematopoietic stem and progenitor
cells (HSPCs), with the highest levels of expression in megakar-
yocyte erythroid progenitors (MEPs). We discovered that POGZ
is essential for normal murine embryonic development, and un-
covered a function of POGZ in the regulation of embryonic
b-like globin expression in vitro and in vivo. Using mouse models
that conditionally delete Pogz in adult mice, we demonstrate that
Pogz is intrinsically required for normal globin switching, in part,
by regulating Bcl11a expression. Furthermore, we show that
knockdown of POGZ expression in human erythroid cells dere-
presses fetal globin expression. Our data provide evidence
that Pogz is a regulator of mouse embryonic b-like globin expres-
sion and human fetal hemoglobin expression.
RESULTS
Pogz Is Expressed in Normal Murine Hematopoietic
Stem and Progenitor Cells
We identified POGZ, a zinc-finger-containing protein, in a
screen of the human hematopoietic progenitor cell line KG1,
whose potential transcription factor activity and function in
hematopoiesis were unknown (Gudmundsson et al., 2007).
POGZ is expressed in KG1 cells, and POGZ RNA and protein
levels are decreased during differentiation, suggesting that
POGZ may function in hematopoietic cells (Figures 1A and
1B). POGZ is highly conserved from zebrafish to humans,
with "90% homology in coding sequence between human
and mouse and 94% homology in amino acid sequence (Fig-
ure S1A). We performed a detailed analysis of Pogz expression
in purifiedmouse HSPC populations and confirmed that Pogz is
expressed in normal HSCs and common lymphoid progenitors
Figure 1. The Zinc-Finger Protein POGZ Is a Nuclear Protein
Expressed in Human and Mouse Hematopoietic Cells
(A) Real-time qPCR analysis reveals thatPOGZ expression is downregulated in
KG1 cells after treatment with phorbol 12-myristate 13-acetate and tumor
necrosis factor a (TNF-a). Experiments were performed in triplicate, and data
are presented as mean ± SD
(B) Western blot analysis shows reduced POGZ protein levels upon differen-
tiation of KG1 cells.
(C) Real-time qPCR analysis of Pogz expression in purified mouse
hematopoietic stem cells (HSCs), common lymphoid progenitors (CLPs),
common myeloid progenitors (CMPs), granulocyte macrophage pro-
genitors (GMPs), and megakaryocyte erythroid progenitors (MEPs). Gene
expression was normalized to b-actin expression. Experiments were
performed in triplicate, and data are presented as mean ± SD. *p < 0.05;
**p < 0.01.
(D)Western blot analysis of POGZ inmouse tissue lysates indicates that POGZ
is expressed in hematopoietic cells. (BL, blood; BM, bonemarrow; LI, liver; SP,
splenocytes; TH, thymocytes). Reduced exposure time is shown for thymus
and spleen due to strong POGZ expression.
(E) Immunofluorescence analysis of mouse erythroleukemia (MEL) cells.
The cells were fixed, permeabilized, and stained with antibodies that
recognize POGZ (red) and the nucleolar protein FIBRILLARIN (green). DNA
was stained with DAPI (blue). POGZ is detected in the nucleus, but not the
nucleolus.
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(CLPs) and is reduced in common myeloid progenitors (CMPs)
and granulocyte macrophage progenitors (GMPs), while Pogz
expression is significantly higher in MEPs (Figure 1C). Inquiry
of Pogz RNA expression in the BioGPS microarray database
(Su et al., 2004) confirmed that Pogz is highly expressed in mu-
rine HSPCs and increased in MEPs and that Pogz is more
broadly expressed in other tissues, including neural and eye tis-
sue (Figure S1B). Finally, we compared POGZ protein expres-
sion in a limited tissue array and found that POGZ protein is
highly expressed in adult mouse thymocytes and splenocytes,
with lower levels of expression in peripheral blood cells (PBCs),
bone marrow cells (BMCs), and liver cells (Figure 1D). Since
POGZ is expressed in erythroid lineage cells, we used mouse
erythroid leukemia (MEL) cells to examine the expression
and subcellular localization of POGZ by immunofluorescence
and determined that POGZ is mainly localized in the nucleus
and is not present in the nucleolus (Figure 1E). Collectively,
these results confirm that POGZ is expressed in normal mouse
HSPCs, MEPs, and MEL cells, suggesting a potential role for
POGZ in megakaryopoiesis and erythropoiesis.
Reduced Output of Hematopoietic Cells and
Deregulation of Genes Required for Erythropoiesis and
Hemoglobin Switching in Pogz!/! FL Cells
To uncover the physiological function of POGZ in hematopoietic
development, we generated a mouse model to inactivate Pogz
gene expression in vivo (Figures S1C–S1F) (Liu et al., 2003).
Figure 2. Pogz!/!Embryos Are Runted, with
Reduced Numbers of Fetal Liver Cells
(A) Pogz!/! mice do not survive beyond birth.
Number and ratio of Pogz+/+, Pogz+/! and Pogz!/!
progeny from intercrosses of mixed background
(C57BL/6J3 1291/SVImJmice) Pogz+/!mice. The
percentages within the parenthesis indicate
observed progeny, and the expected outcome for
these crosses is +/+ 25%, +/! 50%, and!/! 25%.
(B) Gross morphology of E15.5 Pogz+/+ and
Pogz!/! embryos.
(C) Total fetal liver cellularity in E16.5 Pogz+/+ (n = 2),
Pogz+/! (n = 2) and Pogz!/! (n = 4) embryos. Data
are presented as mean ± SD. **p < 0.01. These
data are representative of 5 separate litters.
We did not detect Pogz!/! pups at
weaning in crosses of Pogz+/! mice,
suggesting that the Pogz!/! mice died
during embryonic development or shortly
after birth. Further analysis showed that
Pogz!/! embryos rarely survived beyond
embryonic day 16.5 (E16.5) when back-
crossed 10 generations onto C57BL/6J
background mice. Timed-pregnancy
studies showed that some Pogz!/! em-
bryos were absorbed as early as E10.5,
but we observed a consistent drop in an-
imal survival around E15.5 (Figure 2A).
The Pogz!/! embryos were generally
smaller and appeared anemic compared
to their wild-type littermates; however, the precise cause of
death is currently unknown (Figure 2B).
Since the FL is the major site of hematopoiesis in the embryo
and Pogz!/! embryos survive until E15.5–E16.5, we harvested
FL cells from Pogz+/+ and Pogz!/! embryos to examine lineage
development by flow cytometry and performed differential gene
expression analysis to identify potential pathways and target
genes affected by the loss of Pogz. As expected, Pogz!/! FL
was significantly smaller, with fewer cells (Figure 2C). We found
that the frequency of myeloid (macrophages [Mac1+Gr1!] and
neutrophils [Mac1+Gr1+]) and B cells (CD19+) in Pogz!/! FL
was similar to Pogz+/+ FL; however, their total numbers
were reduced due to the overall reduction in FL cellularity (Fig-
ures S2A–S2C). We observed increased frequencies of more
primitive erythroid cells (S0–S2 cells) in Pogz!/! FL (Figure S2D);
however, the total number of themoremature erythroid cells was
decreased at all stages of development (S3–S5) in Pogz!/! FL
(Figure S2E). Thus, erythroid, B, and myeloid cells are present
in Pogz!/! FL, but in greatly reduced numbers.
Concomitantly, we performed microarray analysis of RNA ex-
pressed in Pogz+/+ and Pogz!/! E14.5 FL cells to identify poten-
tial target genes and pathways affected by the loss of Pogz. We
found that 1,062 genes were differentially expressed in Pogz!/!
versus Pogz+/+ FLs using >1.5-fold change in gene expression
as a cutoff (Table S1). Ingenuity Pathway Analysis (IPA) of differ-
entially expressed genes identified the ‘‘hematological system
and development and function’’ as a top physiological system
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affected, and ‘‘hematological disease’’ as a top disease and
disorder affected (Figure S2F). Differentially expressed genes
were linked to erythrocytosis and hereditary persistence of fetal
hemoglobin (HPFH) and included Jak2, c-kit, and c-myb (all
upregulated) and Bcl11a and Tfrc (both downregulated) in
Pogz!/! FL cells compared to Pogz+/+ FL cells (Figure 3A). Taken
together, the data from the microarray analysis suggests that
loss of Pogz may lead to deregulation of erythropoiesis and
globin gene expression.
Loss of Pogz Expression Leads to Downregulation of
Bcl11a and Increased Embryonic b-like Globin
Expression
Since Pogz is highly expressed in MEPs, and loss of Pogz
expression affects the expression of genes and pathways
required for erythroid development and globin gene expression
(Figure 3A), we determined the expression of known transcrip-
tional regulators of erythroid and globin gene expression,
including Klf1, Klf2, Nfe2, Gata1, Fog1, and Bcl11a, at E16.5 in
Figure 3. Decreased Expression of Bcl11a
and Increased Expression of Embryonic
b-like Globins in Pogz!/! Fetal Liver Cells
(A) Heatmap of differentially expressed genes in
Pogz+/+ and Pogz!/! FL cells, indicating that
genes expressed during erythroid lineage devel-
opment are affected by loss of Pogz expression.
RNAwas isolated from E14.5 Pogz+/+ and Pogz!/!
FL cells (n = 3 for each genotype), and gene
expression was analyzed on Affymetrix Mouse 430
2.0 oligonucleotide arrays (blue indicates low
expression, and red indicates high expression).
(B) Bcl11a and Klf2 expression is downregulated in
Pogz!/! FL cells. RNA was purified from E16.5
Pogz+/+ and Pogz!/! FLs, and Bcl11a, Klf2, Nfe2,
Klf1,Gata1, and Fog1 expression was analyzed by
real-time qPCR. Gene expression was normalized
to b-actin expression. Experiments were per-
formed in triplicate, and data are presented as
mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
(C) Reduction in BCL11A protein levels in Pogz!/!
FL cells. Western blot analysis was performed on
whole-cell lysates generated from E15.5 Pogz+/+
and Pogz!/! FL cells.
(D) Upregulation of embryonic b-like globins in
Pogz!/! FL cells. RNA was purified from E16.5
Pogz+/+ and Pogz!/! FLs and Hbb-y, Hbb-bh1,
Hba-x, and Hbb-b1/2 expression analyzed by real-
time qPCR. Gene expression was normalized to
b-actin expression. Experiments were performed
in triplicate, and data are presented as mean ± SD.
*p < 0.05; **p < 0.01; ***p < 0.001.
Pogz+/+ and Pogz!/! FL by real-time
qPCR. We found that the expression of
Bcl11a and Klf2was significantly reduced
in RNA obtained from E16.5 Pogz!/! FL
cells compared to Pogz+/+ FL cells,
whereas the expression of Klf1, Gata1
and Fog1 was not significantly different
(Figure 3B). We also confirmed a
decrease of Bcl11a expression at the protein level in E15.5
Pogz!/! FL by western blot analysis (Figure 3C). Since
BCL11A is a critical regulator of the switch between fetal and
adult globin expression in definitive erythroid cells (Sankaran
et al., 2008, 2009, 2010b), we analyzed the expression of the
embryonic a- and b-like globins Hbb-y, Hbb-bh1, and Hba-x in
E16.5 Pogz!/! FL RNA. We found that the expression of the
embryonic globins was significantly upregulated in the Pogz!/!
FL compared to Pogz+/+ FL (Figure 3D). Thus, expression of
Bcl11a is decreased and embryonic globin expression is
increased in Pogz!/! FL cells, suggesting that Pogz may func-
tion to regulate embryonic globin gene expression.
Persistence of Embryonic Globin Expression Is Intrinsic
to Pogz!/! Hematopoietic Cells
To determine if the increased expression of embryonic globin
observed in Pogz!/! FL cells was intrinsic to hematopoietic
cells and not an indirect effect due to loss of Pogz function in
the microenvironment, we transplanted 1 3 106 E15.5
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Pogz+/+ and Pogz!/! FL cells into lethally irradiated recipient
mice (Figure 4A).We found no difference in the number of differ-
entiating erythroid cells at all stages of development (S0–S5) in
the bone marrow of mice transplanted with Pogz!/! and
Pogz+/+ FL cells (Figure S3A). Since CD45 is expressed on
more primitive S1, S2, and S3 cells and is decreased during dif-
ferentiation (S4–S5 cells), we gated on donor-derived CD45.2+
cells in mice transplanted with FL cells. Mice transplanted with
Pogz!/! FL showed reduced numbers of S1/S2 cells and no dif-
ference in the number of S3, S4, or S5 cells compared to mice
transplanted with Pogz!/! FL cells, suggesting relatively
normal red cell output after transplantation (Figure S3B). We
obtained RNA from PBCs 5 weeks after transplantation
(short-term reconstitution) and analyzed Hbb-y and Bcl11a
Figure 4. Persistence of Embryonic b-like
Globin Expression Is Intrinsic to Pogz!/!
Erythroid Cells
(A) Summary of FL transplantation experiments.
Hbb-y RNA expression was increased and Bcl11a
decreased in PBCs obtained from mice 5 weeks
after transplantation of Pogz+/+ or Pogz!/! FL
cells. Gene expression was determined by real-
time qPCR and normalized to b-actin expression.
Experiments were performed in triplicate, and data
are presented as mean ± SD.
(B) Representative flow cytometry analysis of
CD71 and Ter119 expression in mice transplanted
with Pogz+/+; Mx1-cre and Pogzf/f; Mx1-cre BMCs
12 weeks post-pIpC treatment (n = 5 for each
genotype). Gates were set around subsets of
differentiating donor (CD45.2+ expression) bone
marrow (BM) erythroid cells (S0–S5) as previously
described (Koulnis et al., 2011). No differences in
the percentages of donor-derived erythroid sub-
sets were observed.
(C and D) Pogz mRNA is not expressed in PBCs
from mice transplanted with Pogzf/f; Mx1-cre
BMCs and treated with pIpC compared to mice
transplanted with control Pogz+/+; Mx1-cre BMCs
(C), while Hbb-y mRNA expression is significantly
increased in PBCs from mice transplanted with
Pogzf/f; Mx1-cre BMCs (D). Experiments were
performed in triplicate. Gene expression was
normalized to b-actin expression.
expression by real-time qPCR in recip-
ient mice reconstituted with Pogz+/+ or
Pogz!/! hematopoietic cells. Hbb-y
expression was significantly upregulated
in all recipient mice that received
Pogz!/! FL cells, whileHbb-y expression
was silenced in recipient mice trans-
planted with Pogz+/+ FL cells (Figure 4A,
left panel). The expression of Bcl11a was
downregulated in mice transplanted with
Pogz!/! FL cells in comparison to mice
transplanted with Pogz+/+ FL cells (Fig-
ure 4A, right panel). Furthermore, anal-
ysis of Hbb-y expression 3 months post
transplantation (long-term reconstitu-
tion) confirmed that Hbb-y expression remained elevated
in mice transplanted with Pogz!/! FL cells, indicating that
Hbb-y expression is not silenced in erythroid cells arising
from long-term reconstituting HSPCs (Figure S4A). Collectively,
these data suggest that loss of Pogz leads to an intrinsic dere-
pression of embryonic b-like globin expression.
While transplantation of Pogz!/! FL cells provides evi-
dence for an intrinsic role of Pogz in regulating embryonic
globin gene expression, we sought to confirm this in a model
where we could delete Pogz in hematopoietic lineage cells in
adult mice and limit the potential of non-cell-autonomous ef-
fects. First, we bred Pogz conditional mice (Pogzf/f) to EpoR-
cre transgenic mice (Heinrich et al., 2004) (Pogzf/f; EpoR-cre);
however, Pogz was variably deleted in this model (data not
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Figure 5. Pogz Regulates the Expression of Bcl11a and Hbb-y in MEL Cells and Fetal Liver Cells
(A) Hbb-y expression is increased in PBC from Pogz+/! compared to Pogz+/+ mice. Gene expression was normalized to b-actin expression (n = 5 per group and
data are presented as mean ± SD, *p < 0.05).
(B) Lentiviral-mediated knockdown of Pogz in MEL cells represses Bcl11a expression and induces Hbb-y expression. RNA was harvested fromMEL cells 72 and
96 hr after transduction with lentiviral vector expressing Pogz shRNA or a control shRNA vector and expression of Pogz, Bcl11a, and Hbb-y analyzed by
real-time qPCR. Gene expression was normalized to b-actin expression. Experiments were performed in triplicate, and data are presented as mean ± SD.
*p < 0.05; ***p < 0.001.
(C) Western blot analysis of POGZ, BCL11A, and ACTIN expression following lentiviral-mediated knockdown of Pogz in MEL cells. Knockdown was performed
with shRNA targeting Pogz or a control shRNA vector, and cell lysates were harvested 72 hr post-transduction.
(D) Photomicrographs of cytocentrifuge preparations of MEL cells 72 hr after lentiviral-mediated knockdown indicating no effect on cell morphology.
(legend continued on next page)
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included), which precluded using these mice for further
studies. Therefore, we bred Pogzf/f mice to Mx1-cre mice
and transplanted BMCs from Pogz+/+; Mx1-cre and Pogzf/f;
Mx1-cre into irradiated recipients to generate chimeric mice
(K€uhn et al., 1995). Six weeks after bone marrow transplanta-
tion (BMT), we treated mice with polyinosinic:polycytidylic
acid (pIpC) to delete Pogz in hematopoietic cells. Twelve
weeks after Pogz deletion we analyzed (1) BMCs to confirm
that Pogz was deleted, (2) PBCs for complete blood cell
(CBC) analysis, (3) BMCs for MEP and erythroid develop-
ment, and (4) PBCs for expression of Pogz and Hbb-y globin.
Pogz was efficiently deleted in the chimeric Pogzf/f; Mx1-cre
transplanted mice (Figure S4B), and results of CBC analysis
of mice 12 weeks after deletion of Pogz were normal, sug-
gesting that Pogz is not required for normal red cell develop-
ment in this model (Figure S4C). No differences in donor
myeloid and B cell reconstitution were observed in mice
transplanted with BMCs that lack Pogz (Figure S5A). No dif-
ference in the frequency or number of differentiating erythroid
cells (S1–S5) was observed in BMCs from Pogzf/f; Mx1-cre
transplanted mice compared to control transplanted mice
(Figure S5B). Further, no significant differences in donor-
derived erythroid cell reconstitution were observed in mice
transplanted with Pogz+/+; Mx1-cre and Pogzf/f; Mx1-cre
BMC when gated on donor-derived CD45.2+ cells, providing
additional evidence that loss of Pogz does not affect normal
adult erythroid cell development (Figure 4B). Since MEPs are
restricted progenitors for erythroid cells and platelets and ex-
press significant levels of Pogz, we examined if loss of Pogz
affects their development. We found no differences in the
number of donor-derived MEPs in BMCs of mice that lack
Pogz (Figure S5C). In addition, there were no differences in
the number of megakaryocyte progenitors (MkPs) and pre-
magakaryocyte/erythroid progenitors in mice transplanted
with Pogz!/! and Pogz+/+ BMCs (Figure S5D), suggesting
that Pogz is not required for the development of erythroid
or megakaryocyte progenitors. Finally, we analyzed the
expression of Pogz, Hba-x, Hbb-bh1, and Hbb-y in PBCs of
transplanted mice. Our data confirmed that Pogz is not ex-
pressed (Figure 4C), while Hbb-y is expressed in all mice
transplanted with Pogzf/f; Mx1-cre BMCs (Figure 4D).
We also found an upregulation of Hba-x and Hbb-bh1
expression in some of the animals (Figure S6A–S6D). Collec-
tively, these data demonstrate that Pogz is intrinsically
required to repress embryonic b-like globin Hbb-y in adult
red blood cells.
Interestingly, we found that the levels of Hbb-y expression
were significantly increased in PBCs from adult Pogz+/! mice
in comparison to Pogz+/+ mice, suggesting that Pogz-mediated
repression of Hbb-y expression is dependent on the levels of
Pogz expression in adult mice (Figure 5A). Furthermore, since
Pogz+/! mice are viable, reproduce, and show no overt pheno-
type, the data suggest that reducing Pogz levels could result in
persistence of embryonic globin expression without significantly
altering erythroid maturation.
Pogz Negatively Regulates Hbb-y Expression, in Part
through Bcl11a
Our data suggest the possibility that POGZ represses Hbb-y
expression, in part by regulating Bcl11a expression. To
determine if Pogz and Bcl11a are coexpressed and develop-
mentally regulated in a similar fashion during erythroid differ-
entiation, we analyzed the expression profile of Pogz and
Bcl11a in sorted erythroid cells from the bone marrow of
normal C57BL/6J mice (Figure S6E). Our analysis shows
that Pogz and Bcl11a are expressed at similar levels in all
erythroid populations (Figures S6F and S6G). As a compari-
son, Gata1 and Klf1 are highly expressed in CD71HITer119+
cells (Figures S6H and S6I). To investigate if Pogz regulates
the expression levels of Bcl11a and Hbb-y, we knocked
down Pogz expression in MEL cells using lentiviral-mediated
delivery of Pogz-specific small hairpin RNA (shRNA) and
analyzed gene expression 72–96 hr post-transduction. The
knockdown resulted in significant reduction in Pogz mRNA
transcripts (Figure 5B) and loss of POGZ protein expression
(Figure 5C), which did not affect MEL cell differentiation (Fig-
ure 5D) compared to control-treated cells. Loss of Pogz
expression in MEL cells resulted in decreased Bcl11a expres-
sion and increased Hbb-y expression levels (Figures 5B and
5C). In addition, we overexpressed Pogz in E16.5 Pogz!/!
FL by retroviral transduction and examined Bclla and Hbb-y
expression (Figure 5E). Enforced expression of Pogz resulted
in upregulation of Bcl11a expression and repression of Hbb-y
expression. Taken together, these data suggest that Pogz
positively regulates Bcl11a and represses Hbb-y expression.
Interestingly, overexpression of Bcl11a did not reduce Hbb-y
expression in Pogz!/! E16.5 FL cells, which suggests that
Pogz may be required for Bcl11a-mediated repression and
that there are additional mechanisms by which Pogz re-
presses mouse embryonic b-like globin (Figure S6J).
To further examine the requirement for BCL11A in Pogz-
mediated regulation of Hbb-y expression, we performed double
knockdown experiments in MEL cells. We found that reducing
either Pogz or Bcl11a expression increases Hbb-y expression
with Bcl11a knockdown showing more efficient derepression
of Hbb-y expression (Figure 6A). Knocking down both Pogz
and Bcl11a did not increase Hbb-y expression above knocking
down Bcl11a alone (Figure 6A). To examine if Bcl11a could
rescue the upregulation of Hbb-y following Pogz knockdown,
we overexpressed Bcl11a in MEL cells transduced with lentiviral
vectors that express shPogz. We found that enforced Bcl11a
expression partially reduces the increase in Hbb-y expression
mediated by Pogz knockdown in MEL cells (Figure 6B), indi-
cating that the Hbb-y derepression upon loss of Pogz is medi-
ated, in part through BCL11A, although additional mechanisms
are likely involved in this model.
(E) Re-expression of Pogz in Pogz!/! FL cells inducesBcl11a and reducesHbb-yRNA expression. Pogz!/! FL cells were harvested at E16.5 and transduced with
a control retrovirus or retroviral vector expressing the Pogz transgene. RNA was harvested 60 hr post-transduction, and expression of Hbb-y, Bcl11a, and Pogz
were analyzed by real-time qPCR. Gene expression was normalized to b-actin expression. Experiments were performed in triplicate, and data are presented as
mean ± SD. *p < 0.05; ***p < 0.001.
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To test whether POGZ can repress Hbb-y through direct regu-
lation of Bcl11a, we performed chromatin immunoprecipitation
(ChIP) assays using MEL cells transduced with control or Pogz
shRNA lentiviral vectors. POGZ binds to the Bcll1a promoter in
Figure 6. POGZ Regulates Hbb-y Expres-
sion, in Part byRegulatingBcl11aExpression
(A) Western blot analysis of POGZ, BCL11A, and
ACTIN protein levels, and real-time qPCR analysis
of Hbb-y expression following lentiviral-mediated
knockdown of Pogz, Bcl11a, or both Pogz and
Bcl11a in MEL cells. MEL cells were transduced
with shRNA targeting Pogz, Bcl11a, or a control
shRNA vector and cell lysates harvested 72 hr post-
transduction. Gene expression was normalized to
b-actin expression. Experiments were performed in
triplicates and data are presented as mean ± SD.
PU, puromycin. BL, blasticidin.
(B) Western blot analysis of POGZ, BL11A and
ACTIN protein levels and real-time qPCRanalysis of
Hbb-y expression following lentiviral mediated
knockdown of Pogz and overexpression of Bcl11a.
Gene expression was normalized to b-actin
expression. Experiments were performed in
triplicates and data are presented as mean ± SD.
*p < 0.05.
(C) ChIP-qPCR analysis demonstrating that POGZ
binds to the Bcl11a promoter (!972) and enhancer
site (+58). POGZ does not bind to a negative con-
trol region on chromosome 17. Sheared chromatin
was prepared from MEL cells following lentiviral-
mediated knockdown of Pogz. Knockdown was
performed with shRNA targeting Pogz or a control
shRNA vector, and cell lysates were harvested
72 hr post-transduction. Chromatin was immuno-
precipitated with an anti-POGZ antibody and a
control antibody. The Bcl11a gene indicating sites
relative to the transcription start site (TSS) that
were examined by ChIP is shown below. Experi-
ments were performed in triplicate, and data are
presented as mean ± SD. *p < 0.05; **p < 0.01;
***p < 0.001.
MEL cells at !972 and is greatly reduced
at !3,469, and POGZ binding to these
sites is significantly reduced in cells
treated with Pogz shRNA (Figure 6C).
POGZ did not show significant binding to
a negative control region on mouse chro-
mosome 17. We also examined a recently
described enhancer element within intron
2 of the human BCL11A gene, which con-
tains three DNase-I-hypersensitive sites
at +55, +58, and +62 kb from the transcrip-
tion start site (Bauer et al., 2013; Canver
et al., 2015). The mouse Bcl11a gene has
orthologous sequences within intron 2
(Bauer et al., 2013). We determined that
POGZ binds the orthologous +58 se-
quences within the enhancer region using
ChIP assays (Figure 6C) and that POGZ
binding to these sites is reduced when
Pogz levels are lowered by shRNA. Taken together, our data sug-
gest that POGZ may be a regulator of Hbb-y expression by
directly or indirectly interacting with the Bcl11a promoter and
the orthologous Bcl11a enhancer elements.
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Reduction of POGZ Expression in Human
Proerythroblasts Leads to Increased Expression of Fetal
Hemoglobin
To investigate whether POGZ regulates fetal globin expression
in human cells, we examined erythroid cells differentiated from
adult human CD34+ HSPCs in a modified two-phase in vitro
erythroid culture system as previously described (Migliaccio
et al., 2002). We confirmed that the purified CD34+ progenitors
undergo erythroid differentiation in vitro by flow cytometry us-
ing CD34, CD45, CD71, and CD235a antibodies (Figure S7A).
After 2 days, the cells in these cultures are predominantly prim-
itive CFU-E and proerythroblasts that are CD34+CD45+
CD235a!CD71low. Most cells undergo further differentiation
to more mature CD34!CD45!CD71+CD235a+ polychromatic
and orthochromatic erythroblasts after 11 days in culture (Fig-
ure S7A). In addition, compared to undifferentiated control
Figure 7. Lentiviral-Mediated Knockdown
of POGZ Expression in Human Proerythro-
blasts Decreases BCL11A Expression and
Increases Fetal Hemoglobin Expression
(A) Western blot analysis of POGZ, BCL11A, and
ACTIN proteins in cell lysates on days 3–14 of
erythroid cultures. Numbers below POGZ and
BCL11A bands indicate normalized protein levels
in relation to ACTIN.
(B) Western blot analysis of POGZ, HBG, and
ACTIN protein levels in CD34+ cell-derived eryth-
roblasts following lentiviral-mediated knockdown
using two separate POGZ shRNA constructs.
Knockdown was performed at day 2 of expansion
culture with control shRNA or shRNAs targeting
POGZ, and cell lysates were harvested 10 days
post-transduction.
(C) Flow cytometry analysis of CD71 and CD235a
expression of erythroid cell cultures in vitro
following lentiviral-mediated knockdown using two
separate POGZ shRNA constructs. Knockdown
was performed at day 2 of expansion culture with
control shRNA or shRNAs targeting POGZ, and
cells were analyzed 10 days post-transduction.
(D) Western blot analysis of POGZ, BCL11A, and
ACTIN protein levels in erythroid cell cultures
in vitro following lentiviral-mediated knockdown of
POGZ or BCL11A. Knockdown was performed at
day 2 of expansion culture with control shRNA
or shRNA targeting POGZ or BCL11A, and cell
lysates were harvested 9 days post-transduction.
(E) Representative bar graphs showing fetal he-
moglobin (HBG1/2) as a percentage total b-globin
(HBB+HBE+HBG1/2) expression following lenti-
viral-mediated shRNA knockdown of POGZ.
Erythroblasts were harvested on day 9 post-
transduction (day 11 of culture), and the quantities
of HBB, HBE, and HBG proteins were determined
by HPLC.
cells (Figure S7B, left panel), the cell pel-
lets became increasingly red, an indica-
tion of increased hemoglobinization and
erythroid differentiation (Figure S7B,
right panel). We found that POGZ and
BCL11A proteins are highly expressed in cells from day 3 cul-
tures (proerythroblasts) and that their expression declines dur-
ing erythroid differentiation, with little expression after
12–14 days in culture (Figure 7A). To investigate whether
POGZ regulates fetal hemoglobin (HBG1/2) expression in hu-
man cells, we transduced primary human CD34+ cells on day
2 of expansion culture with a control lentiviral shRNA vector
or lentiviral shRNA vectors targeting different regions of human
POGZ coding sequence and measured fetal hemoglobin
expression 10 days after transduction by real-time qPCR
and western blot. Real-time qPCR analysis showed that
both POGZ shRNA constructs significantly reduced POGZ
transcript levels compared to control shRNA (Figure S7C).
HBG1/2 expression was significantly upregulated and HBB
expression was significantly downregulated, whereas HBE
and HBA expression were marginally affected (Figure S7C).
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Western blot analysis showed efficient reduction in POGZ pro-
tein expression in cultures transduced with POGZ shRNA con-
structs (Figure 7B), with robust increase in HBG1/2 protein
levels, while POGZ or HBG1/2 protein expression was not
affected in cultures transduced with control shRNA (Figure 7B).
Knockdown of POGZ expression did not affect erythroid differ-
entiation in these cultures, since there was no difference in the
extent of erythroid differentiation (CD71+CD235a+ cells) in
cultures treated with control shRNA and POGZ shRNA
lentiviral vectors after 12 days (Figure 7C). In agreement with
the mouse data above (Figure 5), BCL11A protein levels were
significantly reduced upon POGZ lentiviral-vector-mediated
knockdown, suggesting that POGZ may also regulate
BCL11A expression in human erythroid cells (Figure 7D). In
comparison, POGZ protein levels were minimally affected
following lentiviral-vector-mediated BCL11A knockdown (Fig-
ure 7D). As expected, lentiviral-vector-mediated BCL11A
knockdown signficantly increased HBG1/2 expression (Fig-
ure S7D). HBE expression was also significantly upregulated
and HBB and HBA expression significantly downregulated
(Figure S7D). Finally, knockdown of POGZ results in HBG1/2
protein levels representing roughly 25% of total b-globin, as
assessed by high-performance liquid chromatography
(HPLC), which is therapeutically relevant (Figure 7E). Taken
together, the results suggest that POGZ is a repressor of fetal
hemoglobin expression in humans.
DISCUSSION
In this report, we identified a previously uncharacterized zinc-
finger-containing protein, POGZ, which is expressed in mouse
and human HSPCs and required to repress embryonic hemoglo-
bin gene expression during normal hematopoietic development.
Elevated embryonic globin expression correlated with reduced
expression of Bcl11a, a known repressor of embryonic b-like
globin expression, in Pogz!/! FL cells. We demonstrate, in two
different animal models, that red cells develop normally in the
absence of Pogz in vivo but that the red blood cells (RBCs)
show increased embryonic globin expression. Thus, deregula-
tion of embryonic globin expression is intrinsic to Pogz!/! he-
matopoietic cells, and embryonic globin expression can persist
in adult mice after transplantation. Finally, we show that POGZ
knockdown increases fetal globin expression in primary human
erythroblasts, indicating that POGZ also regulates human fetal
globin expression, which is the focus of our future studies. These
findings are significant since improved therapeutic strategies are
needed to treat hereditary globin disorders (Weatherall, 2010).
Individuals affected by these diseases have moderate to severe
anemia and other serious health issues; however, natural varia-
tions that result in HPFH expression are linked to lessening the
severity of disease (Sankaran et al., 2010a). Therefore, POGZ
may represent a potential therapeutic target to increase fetal
globin expression in patients with SCD and b-thalassemia (Bauer
et al., 2012).
We found that Bcl11a expression is reduced in Pogz!/! FL
cells, MEL cells treated with Pogz shRNA, and human CD34+
progenitors treated with POGZ shRNA, suggesting that Pogz
positively regulates Bcl11a expression in mouse and human
cells. POGZ binding to the Bcl11a promoter and a recently iden-
tified intron 2 enhancer (Bauer et al., 2013; Canver et al., 2015)
suggests that POGZ is directly regulating Bcl11a transcription.
Future experiments, including ChIP sequencing and electropho-
retic mobility shift assays (EMSAs), will determine if this regula-
tion is direct or indirect via interaction with other DNA binding
proteins. We also show that BCL11A does not repress embry-
onic b-like globin Hbb-y when Bcl11a is overexpressed in
Pogz!/! FL erythroblasts, suggesting that POGZ may regulate
embryonic globin expression by mechanisms other than regula-
tion of Bcl11a expression. Since b-actin-Cre-mediated deletion
of Pogz occurs early in development, the absence of Pogz could
affect expression of genes other than Bcl11a, which could
permanently affect BCL11A’s ability to properly function in these
cells. Alternatively, BCL11A may require POGZ expression to
repress embryonic globin gene expression. In support of this hy-
pothesis, overexpression of Bcl11a in MEL cells transduced with
shPogzRNA, where Pogz expression has been knocked down to
10%–15% of control Pogz expression levels, leads to partial
repression of Hbb-y expression. BCL11A has been the focus
of numerous studies to find unique therapeutic targets in SCD
and b-thalassemia (Sankaran et al., 2008, 2009, 2010b). It is hy-
pothesized that reduction of BCL11A expression in patients with
SCD and b-thalassemia could lead to derepression of fetal he-
moglobin, thereby alleviating the symptoms of these disorders
(Bauer et al., 2012). The decrease in Bcl11a expression and
loss of repression of b-like embryonic globin expression upon
loss of Pogz indicates that POGZmay have the same therapeutic
potential.
Mice reconstituted with Pogzf/f; Mx-1-cre BMCs survive and
show normal development of donor-derived MEP and erythroid
lineage cells (S1–S5), as well as lymphoid andmyeloid cells, sug-
gesting that inhibiting POGZ function in adults would not have
deleterious effects on the host hematopoietic system. However,
additional studies are needed to determine whether loss of
POGZ function in adults can affect HSC andmultipotent progen-
itor development and function or affect other systems. Interest-
ingly, we found that Pogz+/! mice, which develop normally and
show no overt phenotypes, show increased embryonic globin
expression levels in PBCs. Importantly, partial reduction of
POGZ in human erythroblasts also derepressed fetal hemoglo-
bin expression to levels reaching over 25% of total b-like globin.
These results suggest that complete ablation of POGZ in vivo
may not be required to obtain therapeutic benefits. Further
in vitro and in vivo studies are needed to determine if this is
feasible.
KLF1 is a master regulator of erythroid development and
b-globin expression (Perkins et al., 1995). Klf1 knockout (KO)
mice die in utero around E15 due to defects in the differentiation
of erythroid cells at the pro-erythroblast stage (Nuez et al., 1995;
Perkins et al., 1995; Pilon et al., 2008). KLF1 represses the
expression of embryonic globins by upregulating the expression
of Bcl11a and promotes adult b-globin expression in definitive
erythroid cells (Tallack and Perkins, 2013; Zhou et al., 2010).
Klf1 expression was not affected by loss of Pogz expression in
FL cells. However, global gene expression analysis of Klf1!/!
erythroid progenitors demonstrates thatPogz is among the signif-
icantly downregulated genes (Pilon et al., 2008). Furthermore,
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analysis of submitted ChIP-sequencing data suggests that KLF1
binds the POGZ promoter in human primary erythroid cells, indi-
cating that POGZ may be a direct KLF1 target (Su et al., 2013).
Recent evidence suggests that POGZ may have physiological
functions in other systems. Specifically, studies analyzing the
genetic basis of autism spectrum disorders (ASDs) and intellec-
tual disability have detected inactivating mutations in POGZ in
some of these patients (Iossifov et al., 2012; Stessman et al.,
2016; Tan et al., 2016;White et al., 2016). Our preliminary studies
also suggest a function for Pogz in the mammalian neural sys-
tem, since loss of Pogz affects the proliferation of mouse neural
progenitor cells in fetal and adult brain (K.O.G., unpublished
data). Interestingly, potential disrupting mutations in the
BCL11A gene have been found in ASDs, and BCL11A has
been implicated in neuronal morphogenesis (Iossifov et al.,
2012; John et al., 2012). In addition, it was shown in two separate
studies that individuals presenting with ASD and developmental
delay had common microdeletions of BCL11A rendering them
haploinsufficient for the gene. Interestingly, these individuals
have elevated expression of fetal hemoglobin (Basak et al.,
2015; Funnell et al., 2015). These data suggest that BCL11A
and POGZ could function within the same regulatory networks
in the neural system.
In summary, our data show that POGZ is essential for normal
embryonic development and that loss of the gene leads to
deregulation of embryonic globin expression, in part through
Bcl11a. Reduction of POGZ expression in erythroid cells could
have therapeutic implications in SCD and b-thalassemia.
EXPERIMENTAL PROCEDURES
Mice
Conventional Pogz!/!mice and conditional Pogzf/f, and Pogzf/f; Mx1-cre mice
were generated as described in Supplemental Experimental Procedures.
Female mice aged 8–12 weeks were used as recipients for all transplantation
experiments. Mice were housed, fed, and handled in accordance with the
National Institutes of Health guidelines for animal care and use and the Guide
for the Care andUse of Laboratory Animals, 8th Edition. All mouse experiments
were reviewed and approved by the Institutional Animal Care and Use
Committee of the National Cancer Institute at Frederick, which is accredited
by Association for Assessment and Accreditation of Laboratory Animal Care
(AAALAC) International.
Real-Time qPCR
Analysis of POGZ expression in KG1 cells by real-time qPCR was performed
as described previously (Gudmundsson et al., 2007). Globin expression was
analyzed in CD34+ HSPC-derived human erythroblasts using Taqman assays.
Formouse FL cells, PBC and BMCRNAwas isolated and real-time qPCR anal-
ysis performed in triplicate using Power SYBR Green PCR Master Mix (Life
Technologies) and a 7500 Real-Time PCR System (Life Technologies) as pre-
viously described (Oakley et al., 2012). The DCt method was used to calculate
relative changes in gene expression. Primer sequences are presented in
Supplemental Experimental Procedures.
Flow Cytometry
Single-cell suspensions were prepared from Pogz+/+ or Pogz!/! FLs or from
BMCs and PBCs from animals transplanted with Pogz+/+ or Pogz!/! FL cells
or Pogz+/+; Mx1-cre or Pogzf/f; Mx1-cre BMCs. Cells were incubated with
the antibodies described in Supplemental Experimental Procedures and
then analyzed by FACS-CantoII (BD Biosciences), and data were analyzed us-
ing FlowJo software (Tree Star).
FL and BMC Transplantations
FL cells were harvested from E14.5–E16.5 Pogz+/+ and Pogz!/! embryos, and
BMCs were isolated from adult Pogz+/+; Mx1-cre and Pogzf/f; Mx1-cre mice
and then transplanted as described in Supplemental Experimental Procedures
using standard methodologies (Gudmundsson et al., 2012, 2014).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism (GraphPad Soft-
ware). An unpaired Student’s t test was used to calculate statistical signifi-
cance. Results were considered significant if p < 0.05. Results are presented
as the mean ± SD.
DATA AND SOFTWARE AVAILABILITY
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GSE113503.
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